<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409461</url>
  </required_header>
  <id_info>
    <org_study_id>4-2001-434</org_study_id>
    <secondary_id>G.0375.00</secondary_id>
    <secondary_id>G.0084.02</secondary_id>
    <secondary_id>GOA/2004/10</secondary_id>
    <nct_id>NCT00409461</nct_id>
  </id_info>
  <brief_title>Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts</brief_title>
  <official_title>Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ-VUB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fund for Scientific Research, Flanders, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Belgian Government</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AZ-VUB</source>
  <brief_summary>
    <textblock>
      Proof of concept study in islet transplantation, two treatment arms (ATG SIR-TAC versus ATG
      SIR) each consisting of ten type 1 diabetic patients
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Islet Transplantation</condition>
  <condition>Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-Sirolimus-Tacrolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 insulin-dependent diabetic patients

          -  C-peptide &lt; 0.15 nmol/l (&lt;0.45 µg/l) 6 min. after glucagon IV (1mg) (glycemia &gt; 180
             mg/dl)

          -  diabetic nephropathy

          -  hypoglycaemic unawareness

        Exclusion Criteria:

          -  smoker before transplantation

          -  plasma creatinine &gt; 2 mg/dl

          -  albuminuria &gt;1000 mg/24 hrs

          -  abnormal liver function

          -  history of thrombosis or pulmonary embolism

          -  history of malignancy, tuberculosis or chronic viral hepatitis

          -  history of any other serious illness which could be relevant for the protocol

          -  HLA antibodies

          -  EBV antibody negative

          -  HIV 1 &amp; 2 antibody positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bart Keymeulen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ-VUB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academisch Ziekenhuis and Diabetes Research Center – Brussels Free University-VUB</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology and Nephrology, UZ Gasthuisberg, Katholieke Universiteit Leuven –KUL</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2006</study_first_submitted>
  <study_first_submitted_qc>December 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2006</study_first_posted>
  <last_update_submitted>December 8, 2006</last_update_submitted>
  <last_update_submitted_qc>December 8, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

